Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc has appointed Richard Cotton as Independent Non-Executive Director, enhancing its board with his extensive financial and life sciences expertise. Cotton’s broad experience in financial leadership and governance within life sciences and other industries, including roles at prominent institutions, positions him to strengthen hVIVO’s strategic initiatives, further cementing its global leadership in the human challenge trial industry and advancing its growth ambitions.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £5.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.
Open Orphan Plc’s overall stock score is driven by strong corporate events and attractive valuation, offset by bearish technical indicators. The company’s financial performance is solid, with growth and profitability, but cash flow management needs improvement. The stock’s undervaluation and positive corporate developments are significant strengths, while technical analysis suggests caution due to current market momentum.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc, a full-service Contract Research Organisation (CRO), is the global leader in human challenge trials, specializing in early-phase clinical development for infectious and respiratory diseases. With state-of-the-art facilities, including the world’s largest quarantine site in London, hVIVO provides end-to-end drug development services, virology and immunology lab solutions through hLAB, and operates clinical trials across Europe via its subsidiaries CRS and Venn Life Sciences.
Average Trading Volume: 4,597,821
Technical Sentiment Signal: Sell
Current Market Cap: £44.66M
See more data about HVO stock on TipRanks’ Stock Analysis page.